Cargando…

Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

INTRODUCTION: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kircik, Leon, Fowler, Joseph, Weiss, Jonathan, Meng, Xiangyi, Guana, Adriana, Nyirady, Judit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120628/
https://www.ncbi.nlm.nih.gov/pubmed/27573260
http://dx.doi.org/10.1007/s13555-016-0139-0
_version_ 1782469273109659648
author Kircik, Leon
Fowler, Joseph
Weiss, Jonathan
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
author_facet Kircik, Leon
Fowler, Joseph
Weiss, Jonathan
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
author_sort Kircik, Leon
collection PubMed
description INTRODUCTION: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance of moderate-to-severe psoriasis. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the head and neck. The safety and overall efficacy of secukinumab in patients with moderate-to-severe psoriasis will be described. METHODS: Data were pooled from four phase 3 studies. To be included in the head and neck analysis, patients were required to have Baseline head and neck Psoriasis Severity Area Index (PASI) scores ≥12 and psoriasis covering ≥10% of the head and neck. Secukinumab (300 or 150 mg) was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48. RESULTS: Secukinumab demonstrated high efficacy on the head and neck and the whole body. At Week 52, head and neck PASI 90/100 subscore responses were achieved by 76.0%/68.7% of patients receiving secukinumab 300 mg, respectively, and by 61.4%/53.1% of patients receiving secukinumab 150 mg, respectively. At Week 52, whole body composite PASI 90/100 responses were achieved by 68.1%/40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6%/24.3% of patients receiving secukinumab 150 mg, respectively. Secukinumab also improved Dermatology Life Quality Index scores. CONCLUSION: Secukinumab provided robust and sustained efficacy for head and neck, and whole body psoriasis, over 52 weeks, with a favorable safety profile. FUNDING: Novartis Pharmaceuticals Corporation. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT01365455, NCT01358578, NCT01555125, and NCT01636687.
format Online
Article
Text
id pubmed-5120628
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51206282016-12-07 Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies Kircik, Leon Fowler, Joseph Weiss, Jonathan Meng, Xiangyi Guana, Adriana Nyirady, Judit Dermatol Ther (Heidelb) Original Research INTRODUCTION: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance of moderate-to-severe psoriasis. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the head and neck. The safety and overall efficacy of secukinumab in patients with moderate-to-severe psoriasis will be described. METHODS: Data were pooled from four phase 3 studies. To be included in the head and neck analysis, patients were required to have Baseline head and neck Psoriasis Severity Area Index (PASI) scores ≥12 and psoriasis covering ≥10% of the head and neck. Secukinumab (300 or 150 mg) was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48. RESULTS: Secukinumab demonstrated high efficacy on the head and neck and the whole body. At Week 52, head and neck PASI 90/100 subscore responses were achieved by 76.0%/68.7% of patients receiving secukinumab 300 mg, respectively, and by 61.4%/53.1% of patients receiving secukinumab 150 mg, respectively. At Week 52, whole body composite PASI 90/100 responses were achieved by 68.1%/40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6%/24.3% of patients receiving secukinumab 150 mg, respectively. Secukinumab also improved Dermatology Life Quality Index scores. CONCLUSION: Secukinumab provided robust and sustained efficacy for head and neck, and whole body psoriasis, over 52 weeks, with a favorable safety profile. FUNDING: Novartis Pharmaceuticals Corporation. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT01365455, NCT01358578, NCT01555125, and NCT01636687. Springer Healthcare 2016-08-30 /pmc/articles/PMC5120628/ /pubmed/27573260 http://dx.doi.org/10.1007/s13555-016-0139-0 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Kircik, Leon
Fowler, Joseph
Weiss, Jonathan
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
title Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
title_full Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
title_fullStr Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
title_full_unstemmed Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
title_short Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
title_sort efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120628/
https://www.ncbi.nlm.nih.gov/pubmed/27573260
http://dx.doi.org/10.1007/s13555-016-0139-0
work_keys_str_mv AT kircikleon efficacyofsecukinumabformoderatetosevereheadandneckpsoriasisover52weekspooledanalysisoffourphase3studies
AT fowlerjoseph efficacyofsecukinumabformoderatetosevereheadandneckpsoriasisover52weekspooledanalysisoffourphase3studies
AT weissjonathan efficacyofsecukinumabformoderatetosevereheadandneckpsoriasisover52weekspooledanalysisoffourphase3studies
AT mengxiangyi efficacyofsecukinumabformoderatetosevereheadandneckpsoriasisover52weekspooledanalysisoffourphase3studies
AT guanaadriana efficacyofsecukinumabformoderatetosevereheadandneckpsoriasisover52weekspooledanalysisoffourphase3studies
AT nyiradyjudit efficacyofsecukinumabformoderatetosevereheadandneckpsoriasisover52weekspooledanalysisoffourphase3studies